Company data sheet · Bio-techne
Bio-techne: ahead of almost everyone like it.
- Industry
- Biological Products,
- Headquarters
- United States
- Ticker
- TECH (Nasdaq)
- Sources
- SEC filings (1995–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- October 18, 2026
- Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 144% in US dollars; the median among 586 large manufacturers grew 58%. It outgrew 81% of them.
- Profitable every year. Bio-techne made money in each of its last eleven fiscal years, from $0.1 billion (fiscal 2025) to $0.3 billion (fiscal 2023).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $0.5 billion | $0.1 billion | |
| 2017 | $0.6 billion | $0.1 billion | |
| 2018 | $0.6 billion | $0.1 billion | |
| 2019 | $0.7 billion | $0.1 billion | |
| 2020 | $0.7 billion | $0.2 billion | |
| 2021 | $0.9 billion | $0.1 billion | |
| 2022 | $1.1 billion | $0.3 billion | |
| 2023 | $1.1 billion | $0.3 billion | |
| 2024 | $1.2 billion | $0.2 billion | |
| 2025 | $1.2 billion | $0.1 billion | |
| 2026 | $1.2 billion | $0.2 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 24 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (17 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.